Combination aerosol therapy to treat Burkholderia cepacia complex

European Respiratory Journal

Volumn 26, Issue 2, 2005, Pages 305-308

  Middleton, Peter G ^a   Kidd, T J ^b   Williams, B ^c  

^a WESTMEAD HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Aerosol; Amiloride; Burkholderia cepacia complex; Cystic fibrosis; Tobramycin

Indexed keywords

AMILORIDE; ANTIBIOTIC AGENT; MUCOLYTIC AGENT; TOBRAMYCIN;

ADULT; AEROSOL; ANTIBIOTIC THERAPY; ARTICLE; ATELECTASIS; BACTERIAL INFECTION; BURKHOLDERIA CEPACIA COMPLEX; CASE REPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MALE; MORBIDITY; MORTALITY; NEBULIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SIDE EFFECT; SPUTUM CULTURE;

ADMINISTRATION, INHALATION; ADULT; AMILORIDE; ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; SODIUM CHANNEL BLOCKERS; TOBRAMYCIN;

EID: 23144458528     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00119504     Document Type: Article

References (16)

1. Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984; 104: 206-210.
2. Cohn RC, Jacobs M, Aronoff SC. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1988; 32: 395-396.
3. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322: 1189-1194.
4. Graham A, Hasani A, Alton EWFW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6: 1243-1248.
5. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995; 8: 1594-1604.
6. Segonds C, Heulin T, Marty N, Chabanon G. Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J Clin Microbiol 1999; 37: 2201-2208.
7. Mahenthiralingam E, Bischof J, Byrne SK, et al. DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol 2000; 38: 3165-3173.
8. Henry DA, Mahenthiralingam E, Vandamme P, Coenye T, Speert DP. Phenotypic methods for determining genomo-var status of the Burkholderia cepacia complex. J Clin Microbiol 2001; 39: 1073-1078.
9. Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001; 33: 1469-1475.
10. Jones AM, Dodd ME, Govan JRW, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004; 59: 948-951.
11. Lipuma JJ, Marks-Austin KA, Holsclaw DS, Jr, Winnie GB, Gilligan PH, Stull TL. Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J 1994; 13: 716-719.
12. Cohn RC, Rudzienski L, Putnam RW. In vitro antimicrobial activity of amiloride analogs against Pseudomonas. Chemotherapy 1992; 38: 232-237.
13. Cohn RC, Rudzienski L. Substituted amines synergistic with tobramycin against Burkholderia cepacia in vitro. Chemotherapy 1997; 43: 100-107.
14. Cohn RC, Aronoff SC. The effect of sodium on amiloride-tobramycin synergy in Pseudomonas cepacia. J Lab Clin Med 1989; 114: 724-727.
15. Gaston B, Ratjen F, Vaughan JW, et al. Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. Am J Respir Crit Care Med 2002; 165: 387-390.
16. Middleton PG, Geddes DM, Alton EWFW. Trimethoprim and tetracycline inhibit airway epithelial sodium absorption. Am J Respir Crit Care Med 1996; 154: 18-23.